Drug Target Review

MAY 22, 2024

Secondly, circRNAs can be engineered for more efficient protein expression by carefully selecting and optimising the IRES element, a sequence motif derived from viruses and used to initiate cap-independent translation from circRNA. What improvements in protein expression and durability have been demonstrated by the circVec 2.1

Therapies 59

Therapies RNA Protein Expression DNA 59

The Pharma Data

DECEMBER 8, 2020

Now poised to advance a robust therapeutics pipeline to clinical development, Nuance will use the funds for ongoing R&D of existing products and business development of potential new assets. Through its Shielded Living Therapeutics platform, the company is developing functional cures for chronic diseases.

RNA 52

RNA Therapies Disease Protein Expression 52

Drug Target Review

SEPTEMBER 10, 2024

Drug developer companies across the pharma industry report notable reductions in drug development timelines where 10 to 12 months, from lead monoclonal antibody (mAb) identification to IND application, is the new norm and in which earlier Tox material generation has been a critical component for shortening IND timelines.

Drug Development 64

Drug Development Clinical Supply Production FDA 64

The Pharma Data

JANUARY 13, 2021

TNX-1500 is a third generation anti-CD40-ligand mAb that has been designed by protein engineering to decrease Fc?RII CD40-ligand is a protein expressed on the surface of activated T lymphocytes that mediates T cell helper function. Second generation anti-CD40-ligand mAbs had dramatically reduced binding to Fc?RII,

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

Alta Sciences

APRIL 17, 2024

They work by binding to specific sequences of nucleotides present within the mRNA structure and can induce mechanisms that either decrease, restore, or modify protein expression. And since proteins are often linked to disease, there's huge potential to treat a broad range of diseases with this technology. Asia, and Europe.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

The Pharma Data

JUNE 7, 2023

Results will be presented on June 6 during an oral presentation (#9004) at the American Society of Clinical Oncology Annual Meeting (#ASCO23). Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).

Trials 40

Trials Protein Expression Therapies Treatment 40

The Pharma Data

AUGUST 9, 2021

We believe this highly sophisticated and specifically engineered ADC is fulfilling its promise to reshape the treatment of HER2-positive metastatic breast cancer, with the goal to move into earlier lines of treatment for HER2-positive breast cancer and many other HER2-expressing tumour types across our broad clinical trial programme.”.

Trials 52

Trials Treatment Clinical Trials Protein Expression 52